Elutia Inc. SEC Filings

Elutia Inc. (ELUT) director David Colpman reported buying additional shares of the company’s Class A common stock. On 11/17/2025, he purchased 15,500 shares at a price of $0.74 per share. Following this transaction, he beneficially owned 18,598 shares, held as a direct ownership position. This filing reflects an insider open-market purchase rather than a sale.

Elutia Inc. (ELUT) filed its Q3 2025 10‑Q, highlighting a business refocus and discontinued operations. From continuing operations, net sales were $3,323 (thousands) versus $3,662 a year ago, with gross profit of $1,853 and a loss from operations of $5,208. Net loss from continuing operations was $383 for the quarter.

The company classified its cardiac implantable electronic device business as discontinued operations and completed its sale on October 1, 2025 for up to $88 million in cash, including $80.3 million paid at closing and $8 million in escrow for twelve months. Discontinued operations posted a quarterly net loss of $3,485. Cash and cash equivalents were $4,721 at September 30, 2025, with total liabilities of $73,325 and a warrant liability of $4,030. Management believes existing cash plus CIED sale proceeds, net of SWK debt repayment, fund operations for at least one year after issuance. On November 7, 2025, Nasdaq notified Elutia of non‑compliance with the $1.00 minimum bid price, with a 180‑day compliance period.

Elutia Inc. reported a Nasdaq bid-price deficiency. The company received notice that its Class A common stock closed below $1.00 for 30 consecutive business days, triggering non-compliance with Nasdaq Listing Rule 5550(a)(2). Trading on The Nasdaq Capital Market continues under “ELUT.”

Elutia has a 180‑day compliance period ending on May 6, 2026 to regain compliance. The company will be deemed compliant if its closing bid price is at least $1.00 for a minimum of ten consecutive business days, after which Nasdaq will confirm compliance. If unmet, Elutia may qualify for an additional 180 days if it meets other listing standards and notifies Nasdaq it may use a reverse stock split. Failing these steps could lead to delisting. Elutia plans to monitor its stock price and evaluate options.

Elutia (ELUT) reported Board changes. The Board elected Guido Neels effective October 9, 2025, and appointed him to the Audit Committee. In line with the non-employee director policy, he received an option to purchase 171,916 shares at an exercise price of $0.88 per share, vesting in three equal annual installments and becoming fully exercisable on October 9, 2028.

The company noted an existing consulting agreement with Mr. Neels from December 1, 2023, under which he was granted 50,000 RSUs on December 20, 2023 and 25,000 RSUs on March 5, 2025, each vesting in quarterly installments through December 2025. Separately, Maybelle Jordan and W. Matthew Zuga resigned from the Board effective October 8, 2025, and the company stated their resignations were not due to any disagreement.

Elutia Inc. (ELUT) reported a director stock option grant covering 171,916 shares at an exercise price of $0.88 on October 9, 2025. The option vests in three equal annual installments and becomes fully exercisable on October 9, 2028, with an expiration date of October 9, 2035. After the grant, 171,916 derivative securities were beneficially owned, held directly.

Elutia Inc. (ELUT) filed a Form 3 reporting a director’s holdings. The filing lists 62,500 shares of Class A Common Stock beneficially owned, held directly. It also discloses restricted stock units granted on December 20, 2023 for 50,000 RSUs vesting in eight equal installments through December 1, 2025, and on March 5, 2025 for 25,000 RSUs vesting in four equal installments through December 10, 2025. The event date is October 9, 2025.

Elutia Inc. announced the closing of a sale of substantially all assets related to its cardiac implantable electronic device (CIED) business to Boston Scientific Corporation and Cardiac Pacemakers, Inc., under an Asset Purchase Agreement dated September 8, 2025. As part of the transaction, Elutia Med LLC amended its royalty agreement with Ligand Pharmaceuticals: Ligand agreed to consent to the sale and released its security interest in the CIED assets, and Elutia Med paid $1.1M in accrued unpaid royalties. The Royalty Agreement requires a 5.0% royalty on future sales of specified products through May 31, 2027, with annual minimum payments of $4.4M. Exhibits filed include the Asset Purchase Agreement, the Consent/Amendment with Ligand, a press release, and unaudited pro forma financial information.

Elutia Inc. (ELUT) Chief Scientific Officer Michelle LeRoux Williams reported the vesting of restricted stock units on 09/10/2025 that resulted in the acquisition of 12,500 shares of Class A common stock. The filing shows 3,950 shares were withheld to satisfy tax withholding, leaving the reporting person with 97,335 shares beneficially owned after the transaction. The underlying RSU grant of 150,000 was originally made on January 31, 2024, with a defined multi-quarter vesting schedule through December 10, 2026.